Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by stocky65on Mar 07, 2021 10:33am
534 Views
Post# 32738379

KLY and sharing

KLY and sharing

For the time being, I am happy that V.KLY is going down as I want to accumulate more shares (usually trying to be at 50,000 or 100,000 shares per stock). I am a penny stock investor who looks for potentials in penny stocks (cannot afford buying more expensive stocks as I have to feed the family). I buy long and in my TFSA account (if I was more active in buying and selling, I would most likely be much richer now).

I used to invest in an investment club of 10 members for 9 years, but now I am going solo (clubs are great for learning).

My present portfolio includes SZLS.TO, ACDC.CN, HEM.V, BTI.V, SOLR.V and KLY.V. Some time ago, when I did not have a TFSA account, I was watching ONC.TO, recommended it to a friend of mine at a very low price, and he made a killing. Too expensive for me now even though I like its potential.

At present my portfolio is 111% up (but still not a millionaire ).

I like KLY for two things: great idea in development and great potential in upside. I will be accumulating, so please keep it low (just joking). Biotech and biology will be the 21st century sciences as chemistry was for the 20th. Looking to add AI, cobalt and lithium companies and some cheap but prospective cryptocurrency/blockchain ideas in development.
 

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse